SIRPA and cancer: Cancer cells evade macrophage phagocytic activity by overexpressing CD47 [113] Thus, blocking the CD47-SIRPα innate immune checkpoint can be therapeutically exploited to potentiate the killing property of myeloid cells towards cancer cells [197,198].